Almac Group Limited

Almac Group Limited is a global leader in drug development services, offering comprehensive solutions in research and development, clinical trial supplies, and precision medicine to biopharmaceutical companies worldwide. Founded in 2001, Almac Group Limited operates as a provider of drug development services, including API manufacturing and clinical trial supply. The company is headquartered in Craigavon, Northern Ireland. Almac was established by a group of pharmaceutical professionals with extensive industry experience and has since expanded its operations globally, including locations in North America and Asia.

Almac Group specializes in providing a comprehensive range of services across the drug development lifecycle, focusing on R&D, diagnostic services, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply services, and commercial-scale manufacturing and distribution. The company’s core product offerings include precision medicine solutions that support drug development for small and highly potent molecules and peptides. Their services are designed to streamline the path to market for biopharmaceutical companies, aiding in the development of new molecular entities and gene therapy products. Almac's client base encompasses leading global biopharma companies, and they serve markets in North America, Europe, and Asia, addressing the needs of both established pharmaceutical firms and emerging biotech companies.

Almac Group has achieved significant financial milestones, surpassing GBP 1 billion in revenue as reported in their latest financial statements. The company operates on a B2B model, engaging with its clients through structured partnerships and contracts, where services are tailored to meet specific project needs. Transactions typically occur through service agreements involving API manufacturing, formulation development, and clinical supply chain solutions, with clients engaging in multi-year partnerships for ongoing support. Almac’s flagship products and services, such as its state-of-the-art manufacturing capabilities and innovative diagnostic solutions, are integral to its revenue model, allowing for flexible pricing plans that accommodate varying project scopes and timelines.

These offerings contribute to sustained growth and a strong position within the global biopharmaceutical market.